DK1227810T3 - Behandling af cancer ved at foröge intracellulære malonyl-CoA-niveauer - Google Patents
Behandling af cancer ved at foröge intracellulære malonyl-CoA-niveauerInfo
- Publication number
- DK1227810T3 DK1227810T3 DK00978553T DK00978553T DK1227810T3 DK 1227810 T3 DK1227810 T3 DK 1227810T3 DK 00978553 T DK00978553 T DK 00978553T DK 00978553 T DK00978553 T DK 00978553T DK 1227810 T3 DK1227810 T3 DK 1227810T3
- Authority
- DK
- Denmark
- Prior art keywords
- fatty acid
- inhibition
- cpt
- malonyl coa
- fas
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2510/00—Detection of programmed cell death, i.e. apoptosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Epoxy Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16476899P | 1999-11-12 | 1999-11-12 | |
US16476599P | 1999-11-12 | 1999-11-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1227810T3 true DK1227810T3 (da) | 2006-10-23 |
Family
ID=26860829
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK00978553T DK1227810T3 (da) | 1999-11-12 | 2000-11-13 | Behandling af cancer ved at foröge intracellulære malonyl-CoA-niveauer |
Country Status (12)
Country | Link |
---|---|
US (1) | US20020187534A1 (fr) |
EP (1) | EP1227810B8 (fr) |
JP (1) | JP2003513920A (fr) |
KR (4) | KR20090130151A (fr) |
AT (1) | ATE330598T1 (fr) |
AU (3) | AU784495B2 (fr) |
CA (1) | CA2391277A1 (fr) |
DE (1) | DE60028996T2 (fr) |
DK (1) | DK1227810T3 (fr) |
ES (1) | ES2267587T3 (fr) |
PT (1) | PT1227810E (fr) |
WO (1) | WO2001034145A1 (fr) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4564714B2 (ja) * | 2000-11-27 | 2010-10-20 | ミナーヴァ・バイオテクノロジーズ・コーポレーション | 診断用腫瘍マーカー、腫瘍形成の阻害のための薬物スクリーニング、並びにがん治療用の組成物及び方法 |
WO2003037323A2 (fr) * | 2001-10-26 | 2003-05-08 | MEDIGENE AG Gesellschaft für Molekularbiologische Kardiologie und Onkologie | Inhibiteurs de l'oxydation des acides gras pour la prophylaxie et le traitement des maladies liees a un dysfonctionnement mitochondrial |
MXPA04007556A (es) | 2002-02-08 | 2005-12-05 | Univ Johns Hopkins Med | Estimulacion de cpt-1 como medio para reducir peso. |
CN101633650A (zh) * | 2002-07-01 | 2010-01-27 | 法斯根有限责任公司 | 新化合物、包含该化合物的药物组合物及该化合物的应用方法 |
KR20050111573A (ko) * | 2002-10-31 | 2005-11-25 | 파스젠, 엘엘씨. | 지방산 신타제 억제제에 의한 암 발생 억제 방법 |
CA2515368A1 (fr) | 2003-02-13 | 2004-08-26 | Luciano Rossetti | Regulation de la prise alimentaire et de la production de glucose par modulation des niveaux d'acyl-coa gras de chaine longue dans l'hypothalamus |
CA2534816A1 (fr) | 2003-06-12 | 2004-12-23 | Evan Newell | Systemes et procedes de traitement de maladies inflammatoires et proliferatives humaines et de lesions au moyen d'inhibiteurs du metabolisme des acides gras et/ou d'inhibiteurs glycolytiques |
US7510710B2 (en) | 2004-01-08 | 2009-03-31 | The Regents Of The University Of Colorado | Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor |
ITMI20040230A1 (it) * | 2004-02-12 | 2004-05-12 | Defiante Farmaceutica Lda | Composti ad attivita' antitumorale |
JP2008539238A (ja) * | 2005-04-28 | 2008-11-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド | 治療用二機能性化合物 |
JP2008543734A (ja) | 2005-05-02 | 2008-12-04 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド | 脂肪酸代謝および解糖の阻害を提供する化合物の組み合わせ、または二官能性化合物を用いるヒトの炎症性および増殖性疾患を処置するためのシステムおよび方法 |
US20090202569A1 (en) * | 2006-04-07 | 2009-08-13 | Tetsuo Mashima | Prophylactic/Therapeutic Agent for Cancer |
WO2008106796A1 (fr) * | 2007-03-08 | 2008-09-12 | University Health Network | Induction d'apoptose et inhibition de prolifération cellulaire par modulation de l'activité carnitine palmitoyltransférase 1c |
US8410150B2 (en) | 2007-03-09 | 2013-04-02 | University Health Network | Inhibitors of carnitine palmitoyltransferase and treating cancer |
US20090053804A1 (en) * | 2007-07-27 | 2009-02-26 | Vesta Therapeutics, Inc. | Methods of reducing intracellular fats from mammalian cells |
CA2694724C (fr) * | 2007-08-01 | 2017-09-12 | University Health Network | Inhibiteurs cycliques de la carnitine palmitoyltransferase et traitement anticancereux |
US8394377B2 (en) | 2008-02-21 | 2013-03-12 | The Regents Of The University Of Colorado | Methods for treating cancer using combination therapy |
WO2010008554A2 (fr) | 2008-07-14 | 2010-01-21 | The Regents Of The University Of Colorado | Procédés et produits pour traiter des maladies prolifératives |
JP5317919B2 (ja) * | 2009-10-05 | 2013-10-16 | 花王株式会社 | Gip上昇抑制剤の評価又は選択方法 |
JP6895890B2 (ja) | 2015-02-10 | 2021-06-30 | ミネルバ バイオテクノロジーズ コーポレーション | ヒト化抗muc1* 抗体 |
CA3040637C (fr) * | 2016-10-17 | 2023-02-28 | Keio University | Agent d'elimination de cellules souches indifferenciees, et procede associe |
EP3956663A1 (fr) * | 2019-04-15 | 2022-02-23 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Procédé de profilage du métabolisme énergétique d'une population de cellules |
CN113604573A (zh) * | 2021-09-14 | 2021-11-05 | 北京大学第三医院(北京大学第三临床医学院) | 一种使用至少八种脂肪酸代谢关键酶基因检测方法以及试剂盒 |
CN113549702A (zh) * | 2021-09-14 | 2021-10-26 | 北京大学第三医院(北京大学第三临床医学院) | 一种人脂肪酸代谢关键酶基因检测方法以及试剂盒 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5759837A (en) * | 1989-01-17 | 1998-06-02 | John Hopkins University | Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway |
KR100325766B1 (ko) * | 1992-07-24 | 2002-07-27 | 더 존스 홉킨스 유니버시티 | 암치료를위한지방산합성억제제를함유하는약학조성물 |
US5539132A (en) * | 1994-01-24 | 1996-07-23 | Johns Hopkins University | Cerulenin compounds for fatty acid synthesis inhibition |
US5981575A (en) * | 1996-11-15 | 1999-11-09 | Johns Hopkins University, The | Inhibition of fatty acid synthase as a means to reduce adipocyte mass |
-
2000
- 2000-11-13 KR KR1020097024726A patent/KR20090130151A/ko not_active Application Discontinuation
- 2000-11-13 AT AT00978553T patent/ATE330598T1/de not_active IP Right Cessation
- 2000-11-13 PT PT00978553T patent/PT1227810E/pt unknown
- 2000-11-13 JP JP2001536143A patent/JP2003513920A/ja active Pending
- 2000-11-13 DK DK00978553T patent/DK1227810T3/da active
- 2000-11-13 CA CA002391277A patent/CA2391277A1/fr not_active Abandoned
- 2000-11-13 DE DE60028996T patent/DE60028996T2/de not_active Expired - Fee Related
- 2000-11-13 WO PCT/US2000/031067 patent/WO2001034145A1/fr active IP Right Grant
- 2000-11-13 KR KR1020097004579A patent/KR20090031957A/ko not_active Application Discontinuation
- 2000-11-13 ES ES00978553T patent/ES2267587T3/es not_active Expired - Lifetime
- 2000-11-13 EP EP00978553A patent/EP1227810B8/fr not_active Expired - Lifetime
- 2000-11-13 AU AU16007/01A patent/AU784495B2/en not_active Ceased
- 2000-11-13 KR KR1020077023100A patent/KR20070106648A/ko not_active Application Discontinuation
- 2000-11-13 KR KR1020027006097A patent/KR20020060736A/ko not_active Application Discontinuation
-
2002
- 2002-05-10 US US10/141,859 patent/US20020187534A1/en not_active Abandoned
-
2006
- 2006-07-13 AU AU2006203005A patent/AU2006203005A1/en not_active Abandoned
-
2009
- 2009-10-16 AU AU2009227836A patent/AU2009227836A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1227810B8 (fr) | 2006-08-16 |
AU1600701A (en) | 2001-06-06 |
AU2009227836A1 (en) | 2009-11-05 |
WO2001034145A1 (fr) | 2001-05-17 |
AU784495B2 (en) | 2006-04-13 |
EP1227810A1 (fr) | 2002-08-07 |
ES2267587T3 (es) | 2007-03-16 |
EP1227810B1 (fr) | 2006-06-21 |
US20020187534A1 (en) | 2002-12-12 |
KR20090130151A (ko) | 2009-12-17 |
CA2391277A1 (fr) | 2001-05-17 |
DE60028996T2 (de) | 2007-02-08 |
PT1227810E (pt) | 2006-11-30 |
JP2003513920A (ja) | 2003-04-15 |
ATE330598T1 (de) | 2006-07-15 |
DE60028996D1 (de) | 2006-08-03 |
KR20090031957A (ko) | 2009-03-30 |
KR20020060736A (ko) | 2002-07-18 |
AU2006203005A1 (en) | 2006-08-10 |
KR20070106648A (ko) | 2007-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1227810T3 (da) | Behandling af cancer ved at foröge intracellulære malonyl-CoA-niveauer | |
Tseng et al. | Inhibition of MDA‐MB‐231 breast cancer cell proliferation and tumor growth by apigenin through induction of G2/M arrest and histone H3 acetylation‐mediated p21WAF1/CIP1 expression | |
Anastasiou | Tumour microenvironment factors shaping the cancer metabolism landscape | |
Morris et al. | Pathways for ischemic cytoprotection: role of sirtuins in caloric restriction, resveratrol, and ischemic preconditioning | |
Vriend et al. | The Keap1-Nrf2-antioxidant response element pathway: a review of its regulation by melatonin and the proteasome | |
Mullen et al. | Progress in the development of fatty acid synthase inhibitors as anticancer targets | |
Yang et al. | What has passed is prolog: new cellular and physiological roles of G6PD | |
Izzo et al. | The bidirectional relationship between cancer epigenetics and metabolism | |
Gogebakan et al. | Role of propolis on tyrosine hydroxylase activity and blood pressure in nitric oxide synthase-inhibited hypertensive rats | |
MA27609A1 (fr) | Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique | |
TW200716678A (en) | Administration of HCV protease inhibitors in combination with food to improve bioavailability | |
ATE455550T1 (de) | Verwendung eines extraktes aus angelica sinensis als wachstumsinhibitor von krebszellen in der tumortherapie | |
Li et al. | LFG-500 inhibits the invasion of cancer cells via down-regulation of PI3K/AKT/NF-κB signaling pathway | |
DE602005015319D1 (de) | Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen | |
ATE487475T1 (de) | Heterocyclische verbindungen als nützliche malonyl-coa decarboxylase-hemmer | |
Coronel-Hernández et al. | Aberrant metabolism as inductor of epigenetic changes in breast cancer: therapeutic opportunities | |
Rothmeier et al. | The marine compound spongistatin 1 targets pancreatic tumor progression and metastasis | |
Lange et al. | Hydropersulfides are endogenous antioxidants that inhibit ferroptosis | |
NO20020829D0 (no) | Ny anvendelse av docetaxel for behandling av hepatoma | |
Wang et al. | Apigenin inhibits human SW620 cell growth by targeting polyamine catabolism | |
EP2633856A3 (fr) | Inhibiteurs de lyase de citrate d'ATP pour le traitement du cancer | |
EA200500958A1 (ru) | Дейтерированные производные катехоламина, а также лекарственные средства, содержащие эти соединения | |
Shatanawi et al. | Arginase inhibition suppresses breast cancer cell proliferation | |
Kashyap et al. | Efficacy of selinexor is dependent on IκB-α expression and NF-kb deactivation in multiple myeloma cells | |
최종근 et al. | Comparative Modeling of Human Tyrosinase-an Important Target for Developing Skin Whitening Agents |